Abiomed, Inc. ``Goes Live'' with EzMed Solution From Answerthink and SAP
January 09 2007 - 9:30AM
Business Wire
Answerthink, Inc. (NASDAQ: ANSR), announced today the successful
go-live of EzMed, an SAP All-in-One business software solution, at
Abiomed, Inc., a leading developer, manufacturer, and marketer of
circulatory support technology for patients in heart failure.
Joining a growing list of midsize companies opting for the
industry-specific business management solution from Answerthink and
SAP, Abiomed is one of ten life sciences companies that have
selected EzLifeSciences solutions within the past year.
Headquartered in Danvers, MA, Abiomed currently has exclusive
indications on its ventricular assist devices for potentially
recoverable acute heart failure. To date, more than 8,000 patients
worldwide have been supported with Abiomed devices, including the
AB5000� Circulatory Support System and the BVS� 5000 Biventricular
Support System. Abiomed also developed the Abiocor�, the world�s
first completely self-contained, implantable artificial heart. The
Company�s minimally invasive catheterization lab technologies, the
Impella 2.5 and 5.0, are currently in clinical trials in the U.S.
Answerthink is a leading business and technology consulting firm
that enables companies to achieve world-class business performance.
SAP All-in-One solutions are industry-specific software,
implementation, and training solutions developed by SAP partners
using SAP applications. EzMed is an industry-specific offering from
Answerthink based on best practices from SAP and customized for
growing companies in the medical device industries. It is part of
Answerthink�s EzLifeSciences family of preconfigured solutions that
are designed specifically to help life sciences companies achieve
goals such as streamline new product development, automate medical
device manufacture reporting, and meet regulatory compliance
requirements. �We now have the right business management software
in place to support Abiomed�s strategy to be a global leader in
circulatory care,� said Daniel Lubin, director of IT for Abiomed.
�SAP and Answerthink have provided us with a system that will scale
with our business as it grows, enhance supply chain management,
enable business decision support tools and analysis, and
incorporate the employment of industry best practices." The
project, which was completed in 26 weeks, included core
functionality in the areas of finance, human resources, materials
management, production planning, sales and distribution and quality
management, and is also designed to help support regulatory
requirements from the U.S. Food and Drug Administration. "Abiomed
is exactly the type of company that will benefit from our EzMed
solution,� according to John McGrath, managing director of
Answerthink's SAP Solutions Group. �They are bringing exciting new
products to the market and needed to quickly move to a
best-in-class enterprise software solution. We are looking forward
to the next stages in the rollout of SAP throughout their company.�
About Answerthink Answerthink, Inc. (www.answerthink.com) is a
leading business and technology consulting firm that enables
companies to achieve world-class business performance. By
leveraging the comprehensive database of The Hackett Group,
Answerthink's business and technology solutions help clients
significantly improve performance and maximize returns on
technology investments. Answerthink's capabilities include
benchmarking, business transformation, business applications,
business intelligence, and offshore application development and
support. Founded in 1997, Answerthink has offices throughout the
United States and in Europe and India. About Abiomed Based in
Danvers, Massachusetts, Abiomed, Inc., is a leading developer,
manufacturer and marketer of medical products designed to assist or
replace the pumping function of the failing heart. Abiomed
currently manufactures and sells the AB5000� Circulatory Support
System and the BVS� 5000 Biventricular Support System for the
temporary support of all patients with failing but potentially
recoverable hearts. The Company also developed the AbioCor�
Implantable Replacement Heart. In Europe, Abiomed offers the
minimally invasive Impella� Circulatory Support System under CE
Mark approval. The Impella� 5.0 and 2.5 are investigational devices
limited by Federal Law solely to investigational use in the United
States. Other Impella devices are not yet available for sale in the
United States. For additional information please visit:
www.abiomed.com. Copyright � 2006 SAP AG. All rights reserved. SAP,
R/3, mySAP, mySAP.com, xApps, xApp, SAP NetWeaver and other SAP
products and services mentioned herein as well as their respective
logos are trademarks or registered trademarks of SAP AG in Germany
and in several other countries all over the world. All other
product and service names mentioned are the trademarks of their
respective companies. Data contained in this document serves
informational purposes only. National product specifications may
vary. This press release contains �forward-looking statements''
within the meaning of the Private Securities Litigation Reform Act
of 1995 and involve known and unknown risks, uncertainties and
other factors that may cause Answerthink's actual results,
performance or achievements to be materially different from the
results, performance or achievements expressed or implied by the
forward-looking statements. Factors that impact such
forward-looking statements include, among others, the ability of
the products, services, or practices mentioned in this release to
deliver the desired effect, our ability to effectively integrate
acquisitions into our operations, our ability to attract additional
business, our ability to effectively market and sell our
transformation advisory product offerings and other services, the
timing of projects and the potential for contract cancellations by
our customers, changes in expectations regarding the information
technology industry, our ability to attract and retain skilled
employees, possible changes in collections of accounts receivable,
risks of competition, price and margin trends, changes in general
economic conditions and interest rates as well as other risks
detailed in the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2005 filed with the Securities and Exchange
Commission. We undertake no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Answerthink (NASDAQ:ANSR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Answerthink (NASDAQ:ANSR)
Historical Stock Chart
From Aug 2023 to Aug 2024